SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, ...

Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

A live audio webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on March 2 and set a price ...

We recently published an article titled These 10 Stocks Defied Tuesday’s Bloodbath. In this article, we are going to take a ...

ICON plc, a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Edgewise ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

First Enterprise Orders in Asia ? Expanding P2P's footprint in the region, marking the first commercial orders with a strat ...

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...

Active leads BNP Paribas, Citigroup, JP Morgan, Bank of America, Morgan Stanley and Rabobank set IPTs for the two, three, five, seven, 10, 20, 30 and 40-year tranches at Treasuries plus 75bp area, ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...